Welcome to our dedicated page for Protara Therapeutics news (Ticker: TARA), a resource for investors and traders seeking the latest updates and insights on Protara Therapeutics stock.
Protara Therapeutics, Inc. develops clinical-stage biotechnology programs for cancer and rare diseases. Company news centers on TARA-002, an investigational cell-based therapy being studied for non-muscle invasive bladder cancer and lymphatic malformations, including updates from the ADVANCED-2 trial in BCG-Unresponsive and BCG-Naïve NMIBC patient groups.
Recurring updates also cover IV Choline Chloride, an investigational phospholipid substrate replacement therapy for patients receiving long-term parenteral support. Other company announcements include clinical-conference presentations, FDA designation updates, financial results, equity compensation grants under Nasdaq rules, and capital-raising activity tied to Protara's development-stage pipeline.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Protara Therapeutics (TARA) announced significant updates regarding its clinical programs and financial results for the year ending December 31, 2022. Key highlights include expected data from the Phase 1a ADVANCED-1 trial for TARA-002 in treating non-muscle invasive bladder cancer (NMIBC) in 2Q23, and the initiation of Phase 2 trial activities for TARA-002 in lymphatic malformations (LMs) in 2H23. As of December 31, 2022, the company reported cash and equivalents of $102.3 million, anticipated to fund operations through 2025. However, TARA reported a net loss of $39 million for Q4, partly due to a $29.5 million goodwill impairment charge.
Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company focused on innovative therapies for cancer and rare diseases, announced its participation in two upcoming investor conferences. These include the Cowen 43rd Annual Health Care Conference on March 8, 2023, at 9:50 am ET in Boston, and the Oppenheimer 33rd Annual Healthcare Conference virtually on March 14, 2023, at 1:20 pm ET. Investors can access live webcasts of these events on the Company's website, with recordings available afterward. Protara's lead product, TARA-002, targets non-muscle invasive bladder cancer and lymphatic malformations.